12 Month Price Forecast For AVTR
Distance to AVTR Price Forecasts
AVTR Price Momentum
๐ค Considering Avantor (AVTR)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 2:19 AM UTC
AVTR Analyst Ratings & Price Targets
Based on our analysis of 30 Wall Street analysts, AVTR has a consensus that is bullish. The median price target is $25.00, with forecasts ranging from $22.00 to $31.00. Currently, there are 15 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
With AVTR currently trading at $19.01, the median price forecast suggests a 31.5% upside. The most optimistic forecast comes from Dan Brennan at TD Cowen, projecting a 63.1% upside, while Justin Bowers at Deutsche Bank provides the most conservative target, suggesting a 15.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AVTR Analyst Consensus
AVTR Price Target Range
Latest AVTR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AVTR.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Feb 3, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $26.00 |
Jan 21, 2025 | Raymond James | Andrew Cooper | Outperform | Maintains | $26.00 |
Jan 17, 2025 | UBS | Dan Leonard | Neutral | Downgrade | $25.00 |
Oct 28, 2024 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $28.00 |
Oct 28, 2024 | Baird | Catherine Schulte | Outperform | Maintains | $26.00 |
Oct 25, 2024 | Barclays | Luke Sergott | Overweight | Maintains | $25.00 |
Oct 8, 2024 | UBS | Daniel Brennan | Buy | Maintains | $29.00 |
Sep 26, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $34.00 |
Aug 27, 2024 | Wells Fargo | Brandon Couillard | Overweight | Initiates | $30.00 |
Jul 29, 2024 | Baird | Catherine Schulte | Outperform | Maintains | $27.00 |
Jul 29, 2024 | Stifel | Daniel Arias | Buy | Maintains | $28.00 |
Jul 29, 2024 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $29.00 |
Jul 29, 2024 | TD Cowen | Dan Brennan | Buy | Maintains | $31.00 |
Jul 29, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $31.00 |
Jul 29, 2024 | Barclays | Luke Sergott | Overweight | Maintains | $28.00 |
Jul 15, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $31.00 |
Jul 10, 2024 | Citigroup | Patrick Donnelly | Neutral | Downgrade | $23.00 |
Jul 2, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $27.00 |
Jun 28, 2024 | Barclays | Luke Sergott | Overweight | Maintains | $25.00 |
Apr 29, 2024 | Baird | Catherine Schulte | Outperform | Maintains | $26.00 |
Stocks Similar to Avantor Inc
The following stocks are similar to Avantor based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Avantor Inc (AVTR) Financial Data
Avantor Inc has a market capitalization of $13.05B with a P/E ratio of 18.4x. The company generates $6.82B in trailing twelve-month revenue with a 4.5% profit margin.
Revenue growth is -0.3% quarter-over-quarter, while maintaining an operating margin of +7.3% and return on equity of +5.8%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Avantor Inc (AVTR) Company Overview
About Avantor Inc
Provides critical products and services across industries.
The company operates by offering a wide range of mission-critical products and services to various sectors including biopharma, healthcare, and advanced technologies. It generates revenue through the sale of materials, equipment, and specialized services such as lab support and biopharmaceutical development.
Founded in 1904 and headquartered in Radnor, Pennsylvania, the company serves a global market, providing essential solutions that support scientific research and industrial applications across multiple regions including the Americas, Europe, Asia, and Africa.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
14,500
CEO
Mr. Michael Stubblefield
Country
United States
IPO Year
2019
Website
www.avantorsciences.comAvantor Inc (AVTR) Latest News & Analysis
Life Science Tools Firm Avantor Reports Mixed Q4 Earnings, Forecasts Organic Sales Growth In 2025
3 days agoAvantor Inc (AVTR) reported Q4 net sales of $1.69 billion, a 2% decline year-over-year, missing the consensus estimate of $1.71 billion.
Avantor Inc's missed sales projection signals potential weakness in demand, possibly impacting future growth and stock performance, which could affect investor sentiment.
Avantor, Inc. will hold its Q4 2024 Earnings Conference Call on February 7, 2025, at 8:00 AM ET, featuring key executives and analysts from various financial institutions.
The earnings call provides insights into Avantor's financial performance, strategic direction, and market outlook, influencing investor sentiment and potential stock valuation.
Avantor, Inc. reported Q4 2024 net sales of $1.69 billion (down 2%) and full-year sales of $6.78 billion (down 3%). Q4 net income was $500.4 million; full-year net income was $711.5 million.
Avantor, Inc. reported a decline in net sales and organic growth, impacting investor sentiment. However, steady cash flow and adjusted earnings may suggest resilience in operations.
Avantor, Inc. (AVTR) reported Q3 earnings of $0.27 per share, surpassing the Zacks Consensus Estimate of $0.25 and improving from $0.25 per share in the same quarter last year.
Avantor's earnings beat expectations, indicating strong performance and potential growth, which can boost investor confidence and positively affect stock prices.
Avantor (AVTR) reported its revenue and EPS for Q4 2024, which should be evaluated against Wall Street estimates and year-ago figures for a comprehensive performance assessment.
Comparing Avantor's revenue and EPS with Wall Street estimates and prior year figures reveals trends in performance, guiding investment decisions and market sentiment.
TriLink BioTechnologiesยฎ Partners with Avantorยฎ to Expand Nucleic Acid Solutions in Europe
7 days agoTriLink BioTechnologies has partnered with Avantor to enhance distribution of its nucleic acid products in Europe, the Middle East, and Africa, expanding market reach.
The partnership between TriLink and Avantor enhances market reach for TriLink's products in EMEA, potentially boosting revenue and market share, which may positively impact Maravai's stock performance.
Frequently Asked Questions About AVTR Stock
What is Avantor Inc's (AVTR) stock forecast for 2025?
Based on our analysis of 30 Wall Street analysts, Avantor Inc (AVTR) has a median price target of $25.00. The highest price target is $31.00 and the lowest is $22.00.
Is AVTR stock a good investment in 2025?
According to current analyst ratings, AVTR has 15 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $19.01. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for AVTR stock?
Wall Street analysts predict AVTR stock could reach $25.00 in the next 12 months. This represents a 31.5% increase from the current price of $19.01. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Avantor Inc's business model?
The company operates by offering a wide range of mission-critical products and services to various sectors including biopharma, healthcare, and advanced technologies. It generates revenue through the sale of materials, equipment, and specialized services such as lab support and biopharmaceutical development.
What is the highest forecasted price for AVTR Avantor Inc?
The highest price target for AVTR is $31.00 from Dan Brennan at TD Cowen, which represents a 63.1% increase from the current price of $19.01.
What is the lowest forecasted price for AVTR Avantor Inc?
The lowest price target for AVTR is $22.00 from Justin Bowers at Deutsche Bank, which represents a 15.7% increase from the current price of $19.01.
What is the overall AVTR consensus from analysts for Avantor Inc?
The overall analyst consensus for AVTR is bullish. Out of 30 Wall Street analysts, 15 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $25.00.
How accurate are AVTR stock price projections?
Stock price projections, including those for Avantor Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.